Podcasts about clinical trials

Rebecca Bloom is a former employee benefits and executive compensation attorney who spent more than 25 years helping women navigate cancer, work, insurance, disability coverage, and financial survival. She is the founder and author of When Women Get Sick, a book built from decades inside the legal, workplace, and patient advocacy systems most people only discover after diagnosis.Bloom started in Big Law at Simpson Thacher handling employee benefits and compensation work she originally chose to pay off student loans. Then her mother was diagnosed with breast cancer. Suddenly the language she used in corporate law offices became the language of survival at home. Explanation of benefits forms. Coverage disputes. Second opinions. Disability protections. Medical leave. Bills no one could explain.That collision changed the direction of her life.In this episode, Bloom explains how serious illness quietly turns patients into unpaid administrators managing paperwork, logistics, financial risk, and emotional labor while trying to survive treatment. She breaks down how employer based health insurance shapes nearly every aspect of cancer care in America and why women often carry the invisible burden of protecting everyone else from discomfort while they themselves fall apart.The conversation digs into workplace power, the illusion of the healthcare “safety net,” caregiver exhaustion, and the class divide hiding underneath patient empowerment culture. Bloom explains why educated, insured women with resources still struggle to navigate healthcare bureaucracy and what happens to patients without those advantages.This episode explores cancer care, health insurance, employee benefits, patient advocacy, workplace protections, caregiving, and the structural incentives that force sick people to become project managers of their own survival.RELATED LINKSRebecca BloomWhen Women Get SickBay Area Cancer ConnectionsSimpson Thacher & BartlettFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Plus: Carl Icahn's company agrees to sell auto-service chain Pep Boys. And Ukraine strikes a deal with defense company BAE Systems to manufacture howitzers locally. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Vasanta Pundarika built her career inside healthcare investment banking before launching Lotuspring, an advisory firm focused on women's health and behavioral health. She spent nearly 20 years advising healthcare systems, treatment providers, and growth stage companies on mergers, financing, and operational strategy while watching the industry repeatedly misunderstand the people it claimed to serve.The conversation starts unexpectedly with anthropology, bread, and language. Vasanta explains how she spent years changing the pronunciation of her own name to make other people comfortable before eventually reclaiming it. That thread opens into a much larger discussion about adaptation, identity, and what institutions quietly train people to tolerate.From there, the discussion moves into behavioral health, women delaying care, and the invisible labor that healthcare business models routinely ignore. During COVID, Vasanta noticed men's behavioral health units refilled faster than women's units. The reason had nothing to do with demand. Women were still home managing caregiving responsibilities, children, aging parents, and households while their own mental health collapsed in the background.The episode examines what happens when healthcare companies become “snazzy big brands” before building real clinical substance underneath. Vasanta describes the tension between mission and margin inside healthcare startups, private equity backed care models, and behavioral health expansion. The conversation pushes on who benefits when healthcare scales aggressively, who absorbs the operational pressure, and how patient trust erodes long before executives notice it on a dashboard.They also discuss patient advocacy culture, anthropology as systems analysis, healthcare capitalism, prior authorization, investor language, and why some clinically excellent companies never survive long enough to scale.RELATED LINKSVasanta PundarikaLotuspringWomen's Health HorizonsSakhi for South Asian SurvivorsNACDPrinceton University Anthropology DepartmentFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Clinical trial success depends on more than scientific rigor and operational execution. It also depends on the financial systems that support every stage of a study. In this episode of The Top Line, Zahiah “Zee Zee” Gueddar, senior director of commercial strategy for the Clinical Trial Financial Suite at IQVIA Technologies, discusses why modernizing clinical trial finance has become a strategic priority for sponsors. As trials become more complex, fragmented systems and manual workflows are creating bottlenecks that limit visibility, delay payments and introduce unnecessary risk. Gueddar explains how these challenges affect site relationships, operational efficiency and study performance, and why organizations can no longer afford to treat finance as a disconnected administrative process. The conversation also highlights key indicators of readiness for transformation, from cross-functional alignment to executive sponsorship, and outlines the common pain points study teams face today. Ultimately, success depends on moving toward a connected, transparent and predictable financial model that reduces friction, improves collaboration and supports faster, more reliable clinical trials.See omnystudio.com/listener for privacy information.

Biochemist Suzanne Pfeffer is an expert on the molecular roots of Parkinson's disease. Her work focuses on mutated proteins linked to Parkinson's risk. She's discovered, for instance, that drugs inhibiting one of the proteins can help neurons regrow primary cilia and stave off cell death, reversing disease progression. Since similar drugs are in clinical trials, her findings bring great hope for people with a subtype of Parkinson's and hopefully can be linked to earlier detection through warning signs like REM sleep disruptions and loss of smell. “This is precision medicine,” Pfeffer tells host Russ Altman of the future of Parkinson's disease on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Suzanne Pfeffer Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Suzanne Pfeffer, a professor of biochemistry at Stanford University. (00:03:25) Path into Parkinson's Research How Pfeffer's protein work led to a life-changing work on Parkinson's disease. (00:05:28) Parkinson's Primer The various causes and the effects of the disease on the brain and body. (00:10:26) Lewy Bodies and Dementia How Lewy bodies, synuclein, and dementia relate to Parkinson's disease. (00:11:56) Molecular Trafficking Pfeffer breaks down the effects of LRRK2 and GBA mutations in the brain. (00:16:10) Early Disease Changes Some of the early changes in the body and how they show up as symptomatically. (00:20:04) Current Treatments The limitations of symptom-focused treatments. (00:21:46) Treating Earlier Opportunities for slowing or reversing disease progression when detected earlier. (00:22:32) Targeting LRRK2 Current research on disease treatment & trial challenges. (00:27:33) The Value of Basic Science Why curiosity-driven research can unexpectedly lead to disease breakthroughs. (00:29:33) Future In a Minute Rapid-fire Q&A: biomarkers, brain donation, and better Parkinson's treatments. (00:31:52) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today's show gave us a whole lot to think about... from psychics to revolutionary research to good ol' English! Have a great weekend!!Subscribe on LiSTNR: https://play.listnr.com/podcasts/carrie-and-tommySee omnystudio.com/listener for privacy information.

Dr. Justin Abbatemarco and Sukhun Kang discuss seeding trials and other hidden marketing tactics in clinical trials, and their implications for clinical practice and patient care.  Show citation:  Kang S, Lin I, Ekblom M, and Chang S. Clinical trials that are actually marketing ploys targeting doctors – how seeding trials put profit over patients. The Conversation. 2026;6(5). doi:10.64628/AAI.cxdfhnh9s

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest advancements shaping the future of drug discovery and patient care. Veradermics is making significant strides with its oral minoxidil formulation aimed at addressing female pattern hair loss. The mid-stage clinical trial results have analysts optimistic about Veradermics' potential to capture a significant portion of this underserved market. The oral form of minoxidil, traditionally used in topical Rogaine products, offers a novel delivery method that could enhance patient adherence and improve outcomes, marking an innovative leap in dermatological treatments. Johnson & Johnson is navigating the expiration of Stelara's patent protection with resilience, as Tremfya steps up to fill the revenue gap. With quarterly sales exceeding $2 billion, Tremfya underscores the critical role of strategic lifecycle management and robust product pipelines in weathering patent cliffs. This success highlights the necessity for pharmaceutical companies to sustain growth through a well-rounded portfolio that can absorb such impacts. In oncology, Celcuity has achieved a pivotal milestone with FDA approval for its small molecule inhibitor targeting breast cancer. This therapy promises blockbuster potential and could become a new standard-of-care, expanding treatment options for patients. The approval reflects ongoing innovation in oncology, where small molecules continue to play an essential role alongside biologics in advancing cancer therapies. AI-driven drug discovery is gaining traction as Insilico Medicine partners with CDMO Bora in a potentially $2.5 billion deal. This collaboration underscores AI's transformative potential in accelerating drug discovery and development processes. By leveraging artificial intelligence, Insilico aims to identify new drug candidates more efficiently, expediting their journey from bench to bedside. Kelun-Biotech is marking significant progress with its SAC-TMT program targeting non-small cell lung cancer (NSCLC), filling gaps left by Merck's phase 3 efforts. This development is crucial for providing more tailored therapeutic options in oncology, illustrating how advancements in drug development are driving forward personalized medicine. Roche continues its exploration of Alzheimer's disease treatments with a multifaceted approach that includes both amyloid and tau proteins as targets. While its phase 3 amyloid program is prominent, Roche's interest in tau protein highlights the complexity of tackling neurological disorders and the need for diverse therapeutic strategies. Meanwhile, Biogen remains steadfast in defending its anti-tau Alzheimer's candidate following mixed phase 2 results that showed slowed cognitive decline. Despite stock volatility, this endeavor illustrates the high-stakes nature of Alzheimer's research as companies pursue novel approaches to this challenging disease. Regulatory landscapes are also shifting as Johnson & Johnson halts development of an eye disease gene therapy after disappointing phase 2b results. This move reflects the inherent risks involved in gene therapy and underscores the necessity for thorough evaluation at each clinical stage. Medtronic's recall of its Harmony delivery catheter system due to potential detachment risks serves as a reminder of the paramount importance of safety and quality control in medical device manufacturing. Such recalls impact patient safety and emphasize regulatory vigilance over device reliability. In summary, these innovations demonstrate the dynamic nature of the pharma and biotech industries where cutting-edge science drives progress. Integrating AI into drug discovery, managing product lifecycles post-patent expiry, advancing personalized medicine, and maintaining regulatory diligence collectively shape a landscape focused on improving patient outcomes worldwide. Turning to recent scientific developments: Eli Lilly's presentation at AAIC 2026 on their anti-amyloid Alzheimer's drug Kisunla explores maintenance therapy possibilities once amyloid levels fall below a threshold. This potential shift could signify a paradigm change by extending therapeutic benefits and possibly improving long-term outcomes for patients with Alzheimer's. Biogen's advances with its anti-tau Alzheimer's therapy partnered with Ionis Pharmaceuticals further validate the tau hypothesis. The promising mid-stage data on their antisense drug Diranersen opens opportunities for other companies like Denali Therapeutics to explore similar avenues for treating neurodegenerative diseases. The industry is also witnessing a resurgence in biotech IPOs during 2026's first half, recovering from a sluggish 2025. This surge signals investor confidence in biotechnological innovation while providing capital for advancing research pipelines. Financial activities within the sector are robust as Attovia Therapeutics files for an IPO to fund its competitive pipeline against Sanofi's Dupixent. Meanwhile, Advancell's $315 million Series D funding supports advancing prostate cancer candidates into Phase 3 trials, backed by big pharma confidence in radiotherapy's potential. Lastly, regulatory transparency improves as the FDA resumes releasing drug rejection letters after a temporary pause—a move likely to influence future submissions significantly by offering clearer guidance on regulatory expectations. These developments collectively highlight how scientific innovation and strategic maneuvers transform pharmaceutical landscapes, promising profound impacts on patient care through advanced therapies and novel treatments worldwide. As these trends unfold, they reflect an industry increasingly reliant on technological integration and collaborations to drive future growth and innovation.Support the show

Welcome back Rana McKay! Renu was on a flight to Europe this week so Rana jumped into her seat in the GU Cast studio this week to have a chat about the intriguing ARASEC trial which she presented at the AUA Annual Meeting recently. Plus her thoughts on the ARACOG data presented at ASCO last month. And then a great chat with our other studio guest, Professor Renea Taylor, translational scientist at Peter Mac and Monash University, about the very interesting Early Onset Prostate Cancer project, an international collaboration which herself and Rana are both very involved with, looking at the reasons behind why younger men are turning up with aggressive prostate cancer. This is a Themed Podcast supported by our Gold Partners, Bayer Pharmaceuticals. Even better on our YouTube channelLinks:ARASEC trial at AUA 2026 ARACOG trial at ASCO 2026 

Before any new therapy or medicine is placed on the shelves of a pharmacy, it needs to be tested in humans first.What does that process look like? And who are the people testing these new drugs?Jonathan Webb goes behind the curtain of clinical trials with health reporter Lauren Roberts to take a look at what happens in Australia.You can binge more episodes of the Lab Notes podcast with science editor and presenter Jonathan Webb on the ABC Listen app (Australia). You'll find episodes on animal behaviour, human health, space exploration and so much more.Get in touch with us: labnotes@abc.net.auFeaturing:Lauren Roberts, health reporterFurther information:Richard Scolyer encouraged Australians to enrol in research. Here's how to get involvedAustralian Clinical TrialsThis episode of Lab Notes was produced on the lands of the Gadigal, Ngunnawal and Ngambri people.

Host: Steve Jackson, PharmD Guest: Jahan Aghalar, MD Guest: Ulka Vaishampayan, MD With more treatment options than ever for metastatic castration-sensitive prostate cancer (mCSPC), applying clinical trial data in everyday practice has become increasingly complex. Understanding how differences in trial design, patient populations, and clinical endpoints influence treatment decisions is essential for delivering personalized care. Join Dr. Steve Jackson as he speaks with Drs. Jahan Aghalar and Ulka Vaishampayan about practical approaches to interpreting the evidence and tailoring therapy to the patients in front of you. Dr. Aghalar is an Adjunct Assistant Professor at NYU Grossman Long Island School of Medicine, and Dr. Viashampayan is a Professor of Internal Medicine at the University of Michigan Medical School in Ann Arbor, the Director of the Phase One Program, and co-founder of the Translational and Clinical Research Program at the Rogel Cancer Center.

Brad Power spent years advising major corporations on systems design, process engineering, and decision making before lymphoma shoved him into the patient side of American healthcare. Instead of accepting the experience at face value, he started reverse engineering the machinery around cancer itself. Brad is the founder of Cancer Patient Lab and Open Cancer AI, two projects built around a blunt reality most patients discover too late: the healthcare system rewards people who know how to navigate it. Everyone else risks getting steamrolled by information asymmetry, insurance barriers, administrative friction, and institutional incentives designed around efficiency instead of human survival.The conversation starts with Harvard Business Review and Tumblr blogs before moving directly into the darker architecture underneath modern cancer care. Power explains how hospitals optimize for throughput, how insurance companies reward operational consistency over personalized medicine, and why many patients quietly end up needing a crash course in oncology, reimbursement policy, and behavioral psychology while fighting for their lives.The discussion digs into CAR-T therapy, functional testing, AI assisted decision support, and the growing collision between personalized medicine and standardized care pathways. Power argues that engaged patients often get better outcomes because they learn how to push for off guideline treatments, contest denials, and ask smarter questions. The counterpoint lands hard: patients should never have needed to become experts in the first place.The episode also explores the cultural consequences of AI entering cancer care. OpenAI advertising, data privacy, trust erosion, pharmaceutical influence, and “agentic AI” all collide inside a healthcare economy already drowning in distrust. Power sees artificial intelligence as a force multiplier for patient literacy and access. The larger system still decides who gets approved, who gets delayed, and who gets left behind.By the end, the conversation lands exactly where modern healthcare keeps forcing people to land: survival increasingly depends on learning how the machine works before the machine works on you.RELATED LINKSBrad PowerCancer Patient LabOpen Cancer AIHarvard Business ReviewResearch to the PeopleCAR T Cell TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

My Free tools for sites and researchers: https://coordinare.co/Free EDC Tool: https://crc-edc-sandbox.netlify.app/My substack FREE: https://substack.com/@dansfera1?r=27gh4e&utm_medium=ios&utm_source=profileInato: https://go.inato.com/3VnSro6CRIO: http://www.clinicalresearch.ioMy PatientACE recruitment company: https://patientace.com/Join me at my conference! http://www.saveoursites.comText Me: (949) 415-6256Listen on Spotify: https://open.spotify.com/show/7JF6FNvoLnBpfIrLNCcg7aGET THE BOOK! https://www.amazon.com/Comprehensive-Guide-Clinical-Research-Practical/dp/1090349521/ref=sr_1_1?keywords=Dan+Sfera&qid=1691974540&s=audible&sr=1-1-catcorrText "guru" to 855-942-5288 to join VIP list!My blog: http://www.TheClinicalTrialsGuru.comMy CRC Academy: http://www.TheCRCacademy.comMy TikTok: DanSfera

In March, China became the first country to approve an invasive brain-computer interface beyond clinical trials. The implant, called NEO, is now available to some patients with limb paralysis due to a spinal cord injury. Ira talks with Wired staff writer Emily Mullin about the significance of this milestone. Plus, brain implants aren't the only development: China's entire biotech industry has skyrocketed in recent years. A decade ago, about 8% of new drug molecules were discovered in China. Now it's over 40%. And more clinical trials are now being conducted there than in the U.S. or Europe. Ira talks with health policy researcher So-Yeon Kang, who's been following the Chinese pharma industry's meteoric rise. Guests: Emily Mullin is a staff writer at Wired.  Dr. So-Yeon Kang is an Assistant Professor of Health Management and Policy at Georgetown University.  Other episodes you may enjoy: Advances In Brain-Computer Interfaces For People With Paralysis How China Is Driving Down Electricity Costs With Renewables Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Justin Abbatemarco talks with Sukhun Kang about seeding trials and other hidden marketing tactics in clinical trials, and their implications for clinical practice and patient care.  Read the related article on The Conversation.  Disclosures can be found at Neurology.org. 

We know that clinical trials are a critical lifeline, offering new ways to prevent, detect, diagnose and treat breast cancer. Today, patient advocates are transforming clinical trials by bringing the real-world experiences of patients directly to researchers. By acting as a bridge between science and the community, patient advocates boost enrollment in clinical trials, and help build a lasting trust Today we are speaking with Dr. Lior Braunstein, a radiation oncologist and researcher at Memorial Sloan Kettering Cancer Center, and Dr. Ellen Landsberger, a retired OB-GYN and patient advocate, also at Memorial Sloan Kettering Cancer Center. Together they are working on the ARCHER clinical trial, a study that is investigating a new treatment strategy for HER2-positive metastatic breast cancer. We'll talk about what they are hoping to accomplish through the ARCHER trial, what their collaborative process looks like and how patient advocates in clinical trials can help improve patient outcomes. Key Takeaways: Patient advocates help design better clinical trials The ARCHER trial aims to improve treatment outcomes Patient voices shape research from the very beginning Clinical trials study both treatment and quality of life Better access helps more patients join clinical trials Chapters 00:00:00 – Why patient advocates belong at the clinical trial design table 00:04:44 – From breast cancer survivor to patient advocate 00:07:46 – How advocates shape research and address patient concerns 00:12:08 – Inside the ARCHER trial and its goal to improve metastatic breast cancer treatment 00:19:03 – Measuring quality of life and improving access to clinical trials 00:26:28 – How patients can become advocates and influence future research

00:00: Intro01:15: Flyover of Austin Campus02:34: Samsung Partnership04:24:

By the time the paper hit version 71, Dr. Nirosha Murugan had already done the hard part. The data were real. The experiment had worked. A team of researchers had used a wearable bioreactor to trigger limb regeneration in frogs, a result with obvious implications for regenerative medicine. But the science still wasn't getting over the line. The problem wasn't the work. It was the translation.On this episode of Standard Deviation, host Oliver Bogler talks with Dr. Nirosha Murugan, a biophysicist and Tier II Canada Research Chair in Tissue Biophysics at Wilfrid Laurier University, about what happens when a scientist working at the edges of quantum biology, bioelectricity, and tissue regeneration runs headfirst into the unwritten rules of academic publishing. Murugan's research asks biologists to think beyond molecules and chemistry alone, and to consider the physical signals, electromagnetic fields, and invisible forces that shape development and healing. It is ambitious science. It is also exactly the kind of work that can make gatekeepers nervous.Bogler follows Murugan through the less glamorous part of discovery: the hidden curriculum of getting a paper published, securing scientific credibility, and learning that data do not simply “speak for themselves.” Murugan describes how jargon buried the pitch of her own work, how a lack of editorial support left her at a disadvantage, and how the JEDI program at the Life Science Editors Foundation paired her with a former journal editor who taught her how to structure a manuscript, write a cover letter, and survive peer review.The result was publication in Science Advances, but the larger story is about power. Who gets taught the rules of biomedical research. Who has access to grant writers, editors, and institutional polish. Who is left to brute-force their way through the maze. And how one scientist, having finally found the map, now makes sure her own trainees do not have to learn it the hard way.RELATED LINKSDr. Nirosha Murugan⁠Wilfrid Laurier University⁠Life Science Editors Foundation⁠JEDI Program⁠Science Advances paper on limb regeneration⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Clinical trials are so important. They're how new therapies and treatments and cures are developed for diseases, and how we update our medical knowledge. At the same time, they aren't without risk for our kids and our families. So, how do you decide whether it's worth it? We're breaking down that question with pros, cons, and personal experiences.A huge thank you to our sponsor for this summer season, Real Food Blends! Real Food Blends are the only 100% real food meals thatare ready-to-feed for people with feeding tubes. Offering 8 different meals and 1 snack for adults & kids, it's the closest thing to homemade blenderized tube feeding. Learn more at realfoodblends.com!Links:Fill out our contact form to join upcoming discussion groups!Join The Rare Life newsletter and never miss an update!Follow us on Instagram @the_rare_life!Donate to the podcast or Contact me about sponsoring an episode.

Send us Fan MailAn MRI, a phone call, and four words nobody wants to hear: “You have a perforated bowel.” Zach Koscuik was on the road to a comedy gig when Crohn's disease forced yet another hard pivot, adding to a 25-year history that includes perianal Crohn's, fistulas, abscesses, emergency surgeries, biologics, and three ileocolonic resections. We talk with him about what it's like to grow up sick, manage the stigma that makes people minimize inflammatory bowel disease, and keep showing up to school, work, and life when your body is always negotiating the nearest bathroom.Then the story takes a turn into the world of clinical trials and high-stakes medicine. Zach explains how severe disease and short bowel complications pushed his team toward an autologous stem cell transplant, a process that essentially wipes out and restarts the immune system. We get specific about the testing, chemo, isolation, and the surreal experience of being treated on a cancer floor without having cancer, plus the very real impact of insurance decisions that kept him hospitalized for 43 days.The payoff lands with the kind of news IBD patients barely let themselves hope for: a one-year follow-up colonoscopy that comes back completely clean. We also keep it honest about what remains, including motility issues, joint pain, and the mental aftershocks of medical trauma. Zach closes with a simple challenge for the Crohn's and colitis community: practice equal empathy, because two people can share a diagnosis and live totally different realities. If this conversation hits home, subscribe, share the episode with a friend, and leave a review so more people living with IBD can find it.Links: Find Zach on InstagramInformation on the stem cell trial that Zach didStem Cell Therapy clinical trial site- Clinicaltrials.govLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Dr. Jess Peatross trained in conventional medicine and worked as a hospitalist before she started questioning why so many chronically ill patients kept getting worse inside the healthcare system she trusted. Her perspective carries weight because she spent years following every protocol exactly as taught before walking away from hospital medicine entirely.Raised in Huntington, West Virginia during the opioid crisis, she entered medicine believing the system existed to heal people. Instead, she found hospitals driven by billing codes, liability management, and pharmaceutical dependence while patients with chronic illness, autoimmune disease, mold exposure, and chronic pain cycled endlessly through appointments and prescriptions.Dr. Peatross explains what pushed her toward functional medicine, cannabis therapy, and prevention focused care after watching patients improve only after leaving conventional treatment pipelines behind. The conversation tackles physician burnout, chronic illness stigma, healthcare incentives, and the growing collapse of trust between patients and institutions.The discussion also moves into supplements, environmental toxins, ultra processed food, and the uncomfortable economics behind keeping people permanently sick but continuously billable. Dr. Peatross describes the professional backlash that comes with challenging medical orthodoxy while Matthew connects her experience to the broader erosion of public trust across American healthcare.Together they unpack what happens when patients stop believing the system can help them and start searching elsewhere for answers.RELATED LINKSDr. Jess PeatrossInstagramMarshall UniversityBrave New WeedFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Idiopathic pulmonary fibrosis (IPF) is a progressive and often fatal lung disease, which has unknown causes and no cure. But researchers are working tirelessly to uncover more about this deadly disease. On this episode of the ATS Breathe Easy podcast, host Patti Tripathi interviews pulmonologist and transplant specialist Steven Nathan, MD, about advances in the treatment IPF, the importance of earlier diagnosis, ongoing challenges in treatment and lung transplantation, and promising results from the Phase 3 TETON clinical trials of inhaled treprostinil, which could become a fourth approved therapy for IPF. This episode is sponsored by United Therapeutics. 

Clinical trial support companies are rapidly adopting AI, but sponsors have been more hesitant. Raj Indupuri, CEO of eClinical Solutions, gives the top three reasons behind the holdup in AI agent deployment. He explains the specific pattern of uptake for these agents, the required human-in-the-loop oversight, and how the agents can improve clinical trial velocity. Host Deborah Borfitz also gives the latest news on a highly acclaimed treatment for pancreatic cancer, filling evidence gaps in drug safety during pregnancy, guidelines for routinely collected health data for research purposes, an innovative portal aiding bidirectional communication with patients, and more. Show Notes News Roundup KRAS inhibitor therapy for pancreatic cancer Study in The New England Journal of Medicine  News on the Fred Hutch Cancer Center website  Target trial emulation in rural areas Perspective in the Medical Journal of Australia News on the Griffith University website   AI for improving drug safety during pregnancy Report from the Journal of Medical Internet Research Guidelines on the use of routinely collected data Article in The BMJ New regulatory framework in the U.K. Press release by the Medicines and Healthcare products Regulatory Agency  Participant Engagement Portal Article in JNCI Cancer Spectrum Press release from the Alliance for Clinical Trials in Oncology The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider's look at clinical research today.  

Adjunctive psychosocial interventions and opioid abstinence among patients receiving buprenorphine: A randomized clinical trial JAMA Network Open This randomized clinical trial of 340 adults with opioid use disorder (OUD) taking buprenorphine examined the comparative effectiveness of 2 psychosocial treatments—cognitive- behavioral therapy (CBT) and peer recovery support (PRS)—on opioid abstinence when used as adjunctive therapy to office-based buprenorphine treatment in adults with OUD.  Researchers found that neither PRS, CBT, nor a combination of these psychosocial interventions yielded differential effects on opioid abstinence. These results suggest that adjunctive psychosocial interventions may not enhance buprenorphine treatment outcomes in the early stages of treatment.   Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Send us Fan MailWelcome to Episode 30 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Hosted by Rachael Babin.What does it really take to make cancer care smarter? In this episode of Experts on Point, host Rachael Babin is joined by Associate Professor Jenny Liu and patient advocate Beth Ivimey to explore how precision oncology is reshaping not only cancer treatment but the way clinical trials are designed and delivered. It's a conversation that we hope you will find inspiring - its about combining innovation with compassion—and  its a reminder that some of the biggest advances in oncology may come not only from scientific breakthroughs, but from building systems that put patients at the centre of every decision. Drawing on both clinical expertise and lived experience, they discuss genomic testing, trial navigation, toxicity management, patient partnership and the challenges of ensuring the right patient reaches the right trial at the right time. Together, they reflect on why the future of cancer research depends as much on smarter systems and meaningful collaboration as it does on scientific innovation.We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter,  a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us

A clinical trial has begun enrolling Ebola patients in the Democratic Republic of the Congo to evaluate potential treatment. The World Health Organization said it will assess an antibody and antiviral drug remdesivir. The chief of the Africa Centers for Disease Control and Prevention warned that the ongoing outbreak remains very serious as the DRC has reported more than 400 deaths.

Send us Fan MailIn this double-blind randomized controlled trial, Adrianne and Nim examine whether norepinephrine outperforms dopamine as a first-line vasoactive agent in neonates with fluid-refractory septic shock. The primary outcome, shock reversal at 30 minutes, was not significantly different between groups, at 32 percent for norepinephrine and 46 percent for dopamine. Secondary outcomes including mortality, IVH, NEC, and need for additional vasoactive support were also similar. The episode critically examines the methodological limitations of the study, including unclear sepsis definitions, absence of echo phenotyping, and unusually high starting doses, and asks whether the field needs better tools before these questions can be properly answered.----Norepinephrine versus Dopamine for Septic Shock in Neonates: A Randomized Controlled Trial.Mazhari MYA, Priyadarshi M, Singh P, Chaurasia S, Basu S.J Pediatr. 2025 Jul;282:114599. doi: 10.1016/j.jpeds.2025.114599. Epub 2025 Apr 17.PMID: 40252959 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

Send us Fan MailOBGYN Dr. Richard Myers joins Dr. Erich Schramm to discuss the name change from Polycystic Ovarian Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This syndrome is the combination of three parts: increased polyendocrine hormones (like insulin and androgens), changing metabolism, and differences in ovarian function Dr. Myers explains that the name change to PMOS reflects the changing understanding and focus of the syndrome from a purely ovarian-centered approach to a more holistic, full-body treatment regimen. The doctors also discuss how different patient desires drive different treatment options and the need for individualized, patient-centered care. They finish by looking at new treatments, including GLP-1 and GIP medications that can help address the underlying metabolic components of the PMOS.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/learn/course/recent-research-into-biologics-in-asthma-10830Program DescriptionThis podcast activity provides an in-depth review of several recent trials in severe asthma management, highlighting the ongoing shift in asthma precision medicine towards identifying the right patients for the right treatments. Clinicians will examine clinical data from the NIMBLE trial (depemokimab), alongside the WAYFINDER trial (tezepelumab), as well ZEPHYR 5 (benralizumab), REMOMEPO (mepolizumab), VESTIGE (dupilumab) and VALLIANT (verekitug). This activity will grant clinicians critical insights to move beyond simple exacerbation reduction and precisely align advanced biologic therapies with the underlying cellular biology driving each patient's symptoms.Educational ObjectiveAt the conclusion of this activity, participants should be better able to:Review recent updates in the asthma literature, including recent guideline revisions and evolving clinical trial data for newer biologic therapies.Accredited ProvidersThe National Association for Continuing Education in partnership with the Association for Pulmonary Advanced Practice Providers (APAPP).The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).FacultyCedric Rutland, BS, MD, FCCPVolunteer FacultyUniversity of CaliforniaPulmonary Critical Care Internal Medicine, ProducerRutland Medical GroupNewport Critical Care PhysiciansLake Forest, CADr. Rutland has disclosed the following financial relationships:Consultant: Sanofi (asthma, diabetes, NP, RSV, AD), Boehringer Ingelheim (IPF, PPF), Regeneron (asthma, diabetes, NP, RSV, AD), Chiesi (asthma), Baxter (bronchiectasis), Insmed (bronchiectasis), AstraZeneca (asthma, cough)Advisor/Advisory Board: Sanofi (asthma, AD, NP), Regeneron (asthma, AD), Chiesi (asthma), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough)Speaker: Sanofi (asthma, NP, AD, AFRS, urticaria, EoE), Regeneron (asthma, NP, AD, AFRS, urticaria, EoE), Boehringer Ingelheim (IPF, PPF), AstraZeneca (asthma, cough), Chiesi (asthma), Baxter (bronchiectasis)These relationships have ended within last 24 months:Consultant: GSK (asthma, cough, RSV)Advisor/Advisory Board: GSK (asthma, cough, RSV)Speaker: GSK (asthma, cough, RSV)Diego J. Maselli, MD, FCCP, ATSFProfessor and ChiefDivision of Pulmonary Diseases & Critical CareUT Health at San AntonioDirector, Respiratory Care, University Health SystemDirector, Severe Asthma Program, University Health SystemSan Antonio, TXDr. Maselli has disclosed the following financial relationships:Consultant: AstraZeneca (asthma, COPD), Sanofi/Regeneron (asthma, COPD), GSK ( asthma, COPD), Amgen (asthma, COPD), Insmed (bronchiectasis)Speaker: GSK (asthma, COPD), AstraZeneca (asthma, COPD), Amgen (asthma, COPD), Sanofi/Regeneron (asthma, COPD)All of the relevant financial relationships listed for these individuals have been mitigated.Nurse Planner and Peer ReviewerMarjorie Crabtree, DNP, FNP, ANPHaymarket Medical EducationSteering CommitteeNurse Practitioner Healthcare FoundationAccredited Provider Program DirectorBellevue, WADr. Crabtree has no relevant conflicts of interest with any ACCME-defined ineligible company.Accredited Provider DisclosureNACE staff has no relevant financial relationships to disclose.Intended AudiencePulmonology, allergy/immunology, and critical care clinicians (physicians, nurse practitioners, and physician associates), as well as primary care and geriatric medicine clinicians caring for patients with asthma.Commercial SupportersThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

My new favorite woman Sara Foster is here, and we get real about everything: growing up in Hollywood with David Foster as her dad, our Brody Jenner connection, therapy, low self-esteem, dating after a 20-year relationship, and why she currently has zero interest in compromising for a man. We also talk about building an empire with Erin Foster — from Nobody Wants This to Favorite Daughter — plus the reality of rejection in Hollywood, hustle culture, and why not every woman needs to start a business.A word from my sponsors:Foria: Experience your juiciest and deepest sensual experience with a bottle of Foria. Foria is offering a special deal for our listeners. Get 20% off your first order by visiting https://foriawellness.com/HONEST OR use code HONEST at checkout. Lululemon: Go to https://lululemon.com right now. New styles drop all the time and the colors go fast, so don't wait. And if something doesn't work for you, free returns, always.Wayfair: Get prepped for patio season for way less. Head to https://Wayfair.com right now to shop all things home.K18: Shop at Sephora or get 10% off your first purchase at https://k18hair.com with code KRISTIN.Figs: Get 15% off your first order at https://wearfigs.com with the code FIGSRXCookUnity: Go to http://cookunity.com/HONEST or enter code HONEST before checkout for 50% off your first week.JS Health: https://www.jshealthvitamins.com code HONEST for 15% off your order at checkout.JSHealth Vitamins Berberine+ Clinical Trial† †Individual results may vary. Citruslabs Research Team, 2025, “A Clinical Trial to Evaluate the Effects of a Supplement to Support Blood Sugar Levels, Weight Management, and Other Related Outcomes." These trials were conducted on JSHealth Vitamins USA Berberine+ Formula. Formula may vary by region. Berbevis® for 4x better absorption than standard berberine^. ^Petrangolini, G., Corti, F., Ronchi, M., Arnoldi, L., Allegrini, P. & Riva, A., 2021. Development of an innovative berberine food-grade formulation with an ameliorated absorption: in vitro evidence confirmed by healthy human volunteers pharmacokinetic study. Evidence-Based Complementary and Alternative Medicine 2021:7563889. Available at: https://onlinelibrary.wiley.com/doi/10.1155/2021/7563889*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any diseaseFor more Let's Be Honest, follow along at:@kristincavallari on Instagram@kristincavallari and @dearmedia on TikTokLet's Be Honest with Kristin Cavallari on YouTubeProduced by Dear Media.This episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products, or services referred to in this episode.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Farla Efros is a senior retail executive and former CEO who built and sold companies before facing her own breast cancer diagnosis. She brings that same operational mindset into a healthcare system that expects patients to manage complexity while they are at their most vulnerable.She was on a client call in Spain when the diagnosis came through. A clear mammogram had missed it. An MRI caught it. Within hours, she was ordering binders, building a plan, and structuring her treatment like a turnaround strategy. Every appointment became a meeting. Every doctor faced an agenda with dozens of questions. She paid out of pocket for PET scans that were denied and hired a third party firm to validate her treatment path when her own doctors resisted outside input. The conversation tracks what happens when a high-functioning executive enters a system built on delay, denial, and fragmentation. Efros describes negotiating for tests, managing physician relationships, and assembling an “executive board” of advisors across conventional and alternative care. She calls the experience “the worst client I ever had,” exposing how administrative burden shifts onto patients and families.The tension sits between what worked for her and what is inaccessible to most. Her approach requires confidence, time, and fluency in navigating power. The system rewards that behavior while quietly failing patients who cannot replicate it. Insurance coverage still left her paying out of pocket. Doctors pushed standard protocols over precision medicine. Survivorship offered little support once treatment ended.This episode examines how cancer care operates as a series of incentives rather than a coordinated system, and why patients are forced to become operators just to get through it.RELATED LINKSFarla EfrosFarla Efros on LinkedInF*ck CancerF*ck Cancer on AmazonAccentureCTOAMPULL QUOTES“I treated cancer like the worst client I ever had.”“They wouldn't approve the test, so I paid for it myself.”“Every appointment was a negotiation.”FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The FiltrateJoel Topf kidneyboy.bsky.socialSwapnil Hiremath @hswapnil.medsky.social Pedro Teixeira @nephcrit.bsky.socialSpecial GuestsEwout J. Hoorn, Professor of Medicine Erasmus MC, Netherlands. One of the primary authors.Harish Seethapathy, Assistant physician at Massachusetts General HospitalEditingVipin VergheseThe Kidney Connection written and performed by Timothy YauShow Notes A Randomized Trial of Targeted Hyponatremia Correction in Hospitalized Patients in NEJM Evidence, in PubMed, in NephJCSeethapathy: Severe Hyponatremia Correction, Mortality, and Central Pontine Myelinolysis in NEJM EvidenceMacMillan: Osmotic Demyelination Syndrome in Patients Hospitalized with Hyponatremia in NEJM EvidenceSALSA: Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial in JAMA Internal MedicineSALT 1 and 2: Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia in NEJM Hyponatremia registry: Current treatment practice and outcomes. Report of the hyponatremia registry in Kidney InternationalThe Richard Sterns' article on the lower mortality with more severe hyponatremia: Mortality and Serum Sodium: Do Patients Die from or with Hyponatremia? in CJASNThe European Hyponatremia Guidelines: Clinical practice guideline on diagnosis and treatment of hyponatraemia in The European Journal of EndocrinologyThe American Hyponatremia Guidelines: Diagnosis, Evaluation, and Treatment of Hyponatremia: Expert Panel Recommendations in American Journal of MedicineTreating hyponatremia: damned if we do and damned if we don't by Tom Berl in Kidney InternationalProspective (clamp) versus reactive (rescue) DDAVP in hyponatremia: Safety and efficacy of proactive versus reactive administration of desmopressin in severe symptomatic hyponatremia: a randomized controlled trial in Nature Scientific Reports and as covered in PBFluidsHelbert Rondon's RCT of urea Urea for Chronic Hyponatremia on ClinicalTrials.govTubular SecretionsSwapnil: Catfishing on CatNet: A Novel by Naomi Kritzer (Amazon)Harish: Disney CruiseEdward: Flesh: A Novel (Booker Prize Winner) by David Szalay (Amazon)Pedro: Scrubs reboot (IMDB)Joel: KIDNEYcon

Send us Fan MailIn this double-blind randomized controlled trial from northern India, Nim and Adrianne review whether early hydrocortisone reduces 14-day all-cause mortality in preterm infants with fluid-refractory shock. The primary outcome showed no statistically significant difference between groups, though an 11 percent absolute reduction in mortality in the hydrocortisone group raised clinical interest. A major limitation was the high rate of open-label steroid crossover, with over 70 percent of both groups ultimately receiving hydrocortisone. The study highlights the difficulty of achieving equipoise when clinicians already believe strongly in a therapy, and raises important questions about study design in neonatal shock research.----Early hydrocortisone verses placebo in neonatal shock- a double blind Randomized controlled trial. Dudeja S, Saini SS, Sundaram V, Dutta S, Sachdeva N, Kumar P.J Perinatol. 2025 Mar;45(3):342-349. doi: 10.1038/s41372-025-02222-3. Epub 2025 Feb 13.PMID: 39948354 Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

I hear this from so many of my patients: "Dr. Shelly, I haven't changed anything—not my diet, not my exercise—but I'm gaining weight and my body just doesn't respond the way it used to." If you're a woman in your 40s or 50s, you're probably nodding right now. In this episode, I'm walking you through exactly why menopause causes weight gain, why it has nothing to do with willpower, and what breakthrough new research reveals about Foundayo—an oral GLP-1 medication—and how it helps restore the biological signals that become harder to access during this life stage.  I'm sharing real data from the 2026 American Diabetes Association Scientific Conference, including results from the ATTAIN 1 and ATTAIN 2 clinical trials that show meaningful weight loss across all menopausal stages.  But here's what matters most: the goal during menopause isn't just weight loss—it's aging healthy. You'll learn exactly what that looks like and what you need to focus on right now. Episode Highlights: What menopause actually is ( How estrogen decline drives abdominal fat storage and insulin resistance Why muscle loss and poor sleep compound weight gain How GLP-1 medications work—and what they don't do The ATTAIN trials: weight loss results before, during, and after menopause Strength training, protein intake, and the non-negotiables for sustainable results REFERENCES: Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2. Presented at the 86th Scientific Sessions of the American Diabetes Association, June 2026.   Horn DB, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes. Lancet. 2026.   ClinicalTrials.gov. ATTAIN-2 Trial (NCT05872620).   The Menopause Society. Menopause practice recommendations and patient resources on metabolic changes during menopause. Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this episode, we cut through the hype surrounding one of the fastest-growing trends in health and fitness: peptides. Joining us is Dr. Leigh Baxt, a translational scientist with experience advancing more than 30 therapeutic programs across oncology, metabolic disease, infectious disease, and regenerative medicine. Drawing on her background at Brown University, Stanford University School of Medicine, and Harvard Medical School, Dr. Baxt explains how drugs move from promising laboratory discoveries to proven human therapies, and why that process matters. We explore why peptides have become so popular, how social media has outpaced the science, and what people often misunderstand about anecdotal success stories, animal research, and theoretical mechanisms. We also discuss why many compounds that appear promising early in development never become approved treatments, the biological risks of manipulating growth and repair pathways, and where commonly discussed peptides like BPC-157, TB-500, MOTS-C, and KPV currently stand from an evidence perspective. Finally, we tackle some of the biggest misconceptions surrounding Big Pharma, patentability, regulation, and what consumers should expect as peptide oversight continues to evolve. Whether you're considering peptides yourself or simply want to separate scientific evidence from internet marketing, this episode provides the framework needed to evaluate the claims you're seeing online. Coach VinnyEmail: vinny@balancedbodies.ioInstagram: vinnyrusso_balancedbodiesFacebook: Vinny Russo Dr. ErynEmail: dr.eryn@balancedbodies.ioInstagram: dr.eryn_balancedbodiesFacebook: Eryn Stansfield Dr. Leigh BaxtEmail: baxt.leigh@gmail.com Instagram: sciencemomscicommLeigh collaborates heavily with unbiased science: https://www.unbiasedscience.com/ LEGION 20% OFF CODEGo to https://legionathletics.com/ and use the code RUSSO for 20% off your order!

In this episode, my guest is Dr. Glen Jeffery, PhD, a professor of neuroscience at University College London's Institute of Ophthalmology and a leading expert on how light interacts with mitochondria to shape health and aging. Today, he discusses how red and near-infrared light penetrate deep into the body and improve mitochondrial function and overall health. We also discuss how detrimental modern indoor life has become and why expensive red light panels are likely unnecessary and possibly harmful.By the end, you'll understand sunlight as a biological input your body evolved to depend on and the low-cost, practical steps you can take to get more of it.FULL SHOW NOTES HERE: https://l1nk.dev/bjuu235 Sponsor: Shadowmap  https://app.shadowmap.org/?ref=jonathan&discount=JONATHANJ Code: JONATHANJ   Sponsor: Ra Opticshttps://www.raoptics.com/JONATHANJ Code: JONATHANJ About this guest:Academic Profile: https://profiles.ucl.ac.uk/7465 Google Scholar: https://scholar.google.com/citations?user=UYlObKkAAAAJ&hl=en LinkedIn: https://www.linkedin.com/in/glen-jeffery-441a2b1b/ Timestamps:00:16 Intro02:46 Dr. Glen Jeffery03:14 Love for Science, Undergraduate04:24 Tiina Karu, Photobiomodulation Origins, Mechanisms 06:14 Mechanisms, Cytochrome C Oxydase, Nanowater, Electron Flow10:56 Cytochrome C Oxydase, Extra-Pineal Melatonin, Oxidative Stress12:45 Gerald Pollack, Exclusion Zone (EZ) Water13:45 Red/IR Light Passes Through the Human Body; Optics18:09 Red Light On Fruit Flies; Lifespan, ATP Production21:15 Human Epidemiology; Sunlight, Lifespan, All-Cause Mortality22:35 Sponsor: Shadowmap23:30 Features and Benefits of Shadow Map25:02 Incandescents, lifespan, and more25:02 Incandescent Light Produces the Oldest Flies; Broad Band IR on Lifespan25:48 Incandescent Light Bulbs, Vision 28:19 Evolutionarily Conserved Mitochondria29:03 Long-Wavelength Light & Blood Glucose; Mitochondria32:50 Unpublished CGM Data; Long-Wavelength Light & Blood Glucose36:57 Are Red Light Panels Harmful?; Light Intensities, Precautions, Mitigations43:56 Why Do We See Beneficial Effects From Long-Wavelength Therapy? 46:43 Short-Wavelength Blue Light, Mitochondria, Mechanism49:08 The Built Environment, Actionable Steps 52:24 Sponsor: Ra Optics54:24 Flicker55:24 Retinal Health, Blue Light, Red/IR Light59:09 Clinical Trial for Mitochondrial Disease; Ptosis, Red Light01:02:31 Biophotons, Mitochondrial Communication, Red/NIR on Biophotons 01:13:54 Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Social Media, Substack Newsletter

Men are paying more attention to their health than ever before. From peptides and testosterone therapy to protein intake, metabolic health, and longevity, a growing number of men are looking for ways to stay healthier longer and reduce their risk of cardiovascular disease. On this episode of The Heart of Innovation, Dr. John Phillips and I explore some of the biggest trends shaping men's health today and what they could mean for heart health, vascular health, performance, and quality of life. As both an interventional cardiologist and owner of multiple Game Day Men's Health locations, Dr. Phillips shares what he's seeing firsthand from patients who are becoming increasingly proactive about prevention rather than waiting until problems develop. We discuss: • Why metabolic health has become a major focus for men • The growing interest in testosterone replacement therapy • What patients should know about peptides • The role of protein in maintaining muscle and long-term health • How these trends intersect with cardiovascular and vascular disease prevention • Common misconceptions surrounding men's health treatments • A new project Dr. Phillips is developing to help patients increase healthy protein intake Whether you're interested in longevity, performance, prevention, or simply living a healthier life, this conversation offers a practical look at one of the fastest-growing areas in healthcare.

What happens when a sudden diagnosis gives you only months to live? In this episode of Everyone Dies, we explore what it means to live fully on the threshold of life's final chapters.  https://bit.ly/4ezL0FCFirst, we share the deeply moving, self-written obituary of Nora Patricia Keenan, who passed away from complications of colorectal cancer. With unapologetic honesty, Nora looks back at her journey through chaos, addiction, recovery, and growth, reminding us that a meaningful life isn't about being spotless—it's about being honest and showing up. Then, we dive into a powerful discussion about former Nebraska Senator and University of Florida President Ben Sasse, who was diagnosed with Stage IV pancreatic cancer. Then, we dive into a powerful discussion about former Nebraska Senator and University of Florida President Ben Sasse, who was diagnosed with Stage IV pancreatic cancer. Sasse shared a raw look at how a terminal diagnosis brings acute clarity, his experience on a targeted clinical trial, and how he is spending his limited time with his wife and three children.We close the episode with a beautiful reading of Rev. Henry Scott Holland's classic poem, "Death Is Nothing at All." Timestamps00:00 – Introduction:  Honesty, Grit, and Redeeming the Time 02:18 – Recipe of the Week: Disappearing Dip 02:45 – Nora Patricia Keenan's Incredible Self-Written Obituary 05:46 – Living on the Threshold: Senator Ben Sasse's Journey with Stage IV Cancer 09:54 – Family, Faith and Survival - Sasse's 60 Minutes Interview24:40 – Poem: "Death Is Nothing at All" by Rev. Henry Scott Holland 27:15 – Outro Support the show

Pancreatic cancer is among the most deadly forms of cancer, and it can be difficult to catch early. But there's some good news: Clinical trials of a new drug called daraxonrasib found that it doubled the survival time of patients with advanced pancreatic cancer. And some oncologists are calling it a game changer—not just for pancreatic cancer, but potentially other forms of cancer too. Ira talks with oncologist Zev Wainberg, who led a clinical trial for the drug.  Plus, ALS is a degenerative disease that causes patients to lose their ability to walk, swallow and eventually to breathe. Now, there's a drug for a rare genetic form of ALS that can slow the progression or even reverse some of these symptoms. Ira talks with New York Times health and science reporter Pam Belluck about this new treatment. Guests: Dr. Zev Wainberg is a co-director of UCLA Health's GI Oncology Program. Pam Belluck is a health and science reporter for The New York Times. Other episodes you may enjoy: mRNA Vaccine For Pancreatic Cancer Continues To Show Promise How do clinical trials work, and who can participate? Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode Description: Everyone is calling it nature's Ozempic. That is marketing. And it is doing a total disservice to what berberine actually does. Berberine is not a GLP-1 drug. It does not work the same way. The weight loss outcomes are not comparable. And if you are taking it expecting to drop 15% of your body weight, you are going to be disappointed. But here is what the research actually shows, and why Dr. G takes berberine every single day. The clinical evidence on berberine for blood sugar, cholesterol, insulin resistance, and gut health is genuinely compelling. A three month randomized controlled trial in newly diagnosed type two diabetics showed reductions in HbA1c, fasting blood glucose, and post-meal blood glucose that were comparable to metformin. A 2022 meta analysis confirmed it hits triglycerides, total cholesterol, LDL, blood pressure, and insulin resistance markers simultaneously. And the gut microbiome research is a piece almost nobody is talking about.In this episode, you will learn:  •  What berberine actually does in the body through the AMPK pathway, why it is not a GLP-1, and what to realistically expect from it  • Why standard berberine has a major absorption problem, what dihydroberberine is and why it may deliver 2 to 4 times more into circulation at a fraction of the dose  • Exactly how to buy berberine intelligently, what standardization means on a label, which forms to choose, and what to avoid Dr. G's recommended berberine brands linked in the show notes.Product reviews assess both brand transparency and product quality. If a company doesn't respond to our outreach, it doesn't automatically mean their product is low quality but it does mean they're failing their customers on transparency and communication. We reach out multiple times. No response isn't an oversight, it's a choice. And consumers deserve better. Timestamps: 0:00 - Intro 1:44 - How Berberine Works in the Body (And Why It's Not a GLP-1 Drug) 3:24 - The Weight Loss Reality: What Berberine Can and Can't Do 4:48 - Blood Sugar and Insulin Resistance: Where the Evidence Is Strongest 6:30 - Comparable to Metformin in Some Trials — What That Actually Means 7:42 - Cholesterol, Triglycerides & Cardiovascular Risk: Berberine's Strongest Evidence Base 9:44 - How Dr. G Uses Berberine in His Own Daily Routine 10:38 - Berberine's Underrated Effect on the Gut Microbiome 12:30 - The Big Absorption Problem With Standard Berberine (And the Solution) 14:22 - Dihydroberberine: 2-4x More Bioavailable in Human Trials 15:18 - How to Buy Berberine Intelligently: Standardization, Form & Third-Party Testing 17:00 - Who Should Take Berberine (And Who Shouldn't) Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, Thomas K Varghese, Jr, MD, FACS, is joined by Serena Lofftus, MD, and James Wu, MD, FACS, from UCLA. They discuss Drs Lofftus and Wu's recent article, “Patient-Based Decision Making for Opioid Prescriptions After Ambulatory Breast Operation: A Randomized Clinical Trial,” which evaluated whether incorporating patient choice into postoperative prescribing decisions could reduce opioid prescribing and consumption after ambulatory breast operation without negatively affecting pain control or quality of life.   Disclosure Information: Drs Varghese, Lofftus, and Wu have no relevant financial conflicts of interest to disclose.   To earn 0.25 AMA PRA Category 1 Credits™ for this episode of the JACS Operative Word Podcast, click here to register for the course and complete the evaluation. Listeners can earn CME credit for this podcast for up to 2 years after the original air date.   Lofftus, Serena Y MD1,4; Graham, Danielle S MD, PhD1,4; Le, Julie MD, FACS1,2; Zhu, Catherine Y MD1,3; Kaufman, Noy MD4,5; Huy, Tess C MD1,4; Kusske, Amy M MD, FACS1,4; Teshome, Mediget MD, FACS1,4; Baker, Jennifer L MD, FACS1,4; Wu, James X MD, FACS4,6. Patient-Based Decision Making for Opioid Prescriptions After Ambulatory Breast Operation: A Randomized Clinical Trial. Journal of the American College of Surgeons ():10.1097/XCS.0000000000001974, April 13, 2026. | DOI: 10.1097/XCS.0000000000001974   Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more.   #JACSOperativeWord

About this episode:   Research on the potential impacts of certain medications, vaccines, and interventions on pregnant people and their fetuses is lacking. Much of this is due to culturally perceived risks associated with pregnancy and fears of litigation. In this episode: Ruth Faden, an expert in bioethics, explains how this gap in data can fuel other risks and how to ethically and responsibly include pregnant people in clinical trials. Note: This conversation builds on a recent episode of playing god?, the podcast from the Johns Hopkins Berman Institute of Bioethics. Listen to that episode here. Guest:  Ruth Faden, PhD, MPH, is the Philip Franklin Wagley Professor of Biomedical Ethics and the founding director of the Johns Hopkins Berman Institute of Bioethics.  Host:  Stephanie Desmon, MA, is a former journalist, author, and the director of public relations and communications for the Johns Hopkins Center for Communication Programs.  Show links and related content:  Two Bodies, One Prescription—playing god? COVID-19 Vaccines and Pregnancy—Johns Hopkins Bloomberg School of Public Health The second wave: Toward responsible inclusion of pregnant women in research—International Journal of Feminist Approaches to Bioethics Weighing the Risks and Benefits of Medication Use During Pregnancy—Public Health On Call (October 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌PublicHealthPod on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Breakthroughs depend on research volunteers, but many people have questions about what participating in a trial means, and how to select the right trial for their goals, needs and lifestyle. Listen to audio from this month's Third Thursdays Webinar to hear our panel of experts share what to look for in a trial you're considering and how to navigate the clinical trial process.Like our podcasts? Please consider leaving a rating or review and sharing the series with your community. https://apple.co/3p02Jw0Whether you have Parkinson's or not, you can help move research forward. Join the study that's changing everything at michaeljfox.org/podcast-ppmi.This webinar received support from BlueRock Therapeutics. Learn more at expditestudy.com.Mentioned in this episode:Researchers are studying the link between sense of smell and brain health. People with and without Parkinson's can help by taking a scratch-and-sniff test. It's free, mailed to your home and takes just 15 minutes to complete. mysmelltest.org/getstarted

Send us Fan MailDermatologist Dr. Michael Bernhardt joins Dr. Mitchell Rothstein to discuss the rapidly changing and improving world of chronic skin condition. The two doctors discuss the correlation between chronic skin conditions and allergies, and the role that inflammation play in both. The docs then dive deep into our inflammation system.This informs the next section of the podcast, where the Drs. Bernhardt and Rothstein talk about the landscape of chronic skin condition medications. They explain that these conditions had poor outcomes and ineffective medicines for decades, and that this picture has only changed in the last 4-5 years with new medications that work from the inside out instead of the outside in. They talk about new generations of medication that target the inflammatory signals themselves inside the body, showing rapid relief to otherwise untreatable conditions. They finish with a brief look at what is coming down the pipeline of clinical trials.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In 2020, Emily Mendenhall drove from Washington, DC to Okoboji, Iowa, a town of 800 that swells to 200,000 every summer, and walked into a pandemic that looked nothing like the one dominating national headlines. Inside gas stations and bars, masks marked you as an outsider. In one stop, a man told her family they would not be served if they kept theirs on. Her 6 year old daughter cried, confused. Mendenhall, a medical anthropologist at Georgetown University, did what she always does. She started asking questions. Over months, she interviewed neighbors, former classmates, and local officials, including her own brother in law who helped lead the local COVID response. The result became Unmasked, a case study in how community identity, economics, and politics shaped public health decisions in real time. That work led directly into her latest book, Invisible Illness: A History, from Hysteria to Long COVID, where she tracks a much older problem. Patients with chronic illness, especially women, often fail to meet medicine's demand for proof. Without a clear diagnosis, they lose access to care, insurance coverage, and legitimacy. Mendenhall argues that long COVID did not create this failure. It exposed it.This conversation centers on how healthcare systems reward certainty and punish complexity. Long COVID clinics send patients to 17 specialists without resolution. Insurance structures require diagnoses that many conditions cannot provide. Medical training still struggles to integrate trauma, mental health, and chronic disease into a coherent model of care.Mendenhall brings lived experience into the conversation. After COVID, she dealt with months of fatigue and escalating anxiety that altered her baseline health. She does not claim the label of long COVID, but she understands how quickly the system becomes harder to navigate once symptoms stop fitting clean categories. The stakes are not theoretical. In the United States, access to healthcare, disability benefits, and treatment still depends on whether a condition can be measured, coded, and reimbursed. For millions living with invisible illness, the burden of proof becomes the illness itself.RELATED LINKSEmily MendenhallInvisible Illness: A History, from Hysteria to Long COVIDScience PoliticsGeorgetown UniversityFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Resistance training is one of the most powerful interventions for preserving muscle, supporting metabolic health, and promoting healthy aging—but many patients still find it intimidating or confusing. In this episode, Dr. Kara Fitzgerald sits down with exercise physiologist Brad Currier, PhD, to unpack the newly updated ACSM resistance training guidelines and discuss practical approaches for prescribing exercise across the spectrum, from sedentary adults to elite athletes. In partnership with Timeline, they also review the latest clinical research on Urolithin A, mitochondrial function, muscle recovery, protein, and creatine, offering actionable insights for functional medicine practitioners. Full show notes + references: https://www.drkarafitzgerald.com/fxmed-podcast/ GUEST DETAILS Dr. Brad Currier is Manager of Clinical Trials at Timeline, a Swiss biotech company at the forefront of longevity science for over 15 years. With a background in elite athletics, he went on to earn a PhD in muscle physiology, where his research focused on how exercise and nutrition influence aging and performance. Brad has led numerous clinical trials conducted around the world and published extensively in peer-reviewed journals. He is also the lead author of the American College of Sports Medicine's new position stand on resistance training prescription, helping shape global guidelines for strength training and healthy aging. THANKS TO OUR SPONSOR TIMELINE: http://Pro.timeline.com At the core of Timeline is Mitopure®, a pure and patented form of Urolithin A, shown to improve mitochondrial dysfunction. Learn more & Sign up for a Healthcare Practitioner account at http://Pro.timeline.com Email: care@timeline.com CONNECT with DrKF Want more? Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz YouTube: https://tinyurl.com/hjpc8daz Instagram: https://www.instagram.com/drkarafitzgerald/ Facebook: https://www.facebook.com/DrKaraFitzgerald/ DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb Younger You Practitioner Training Program: https://www.drkarafitzgerald.com/trainingyyi/ Younger You book: https://tinyurl.com/mr4d9tym Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw

Dr. Abud Bakri, MD, is a board-certified internal medicine physician and expert in the science and clinical use of peptides. We discuss the history, uses, sourcing and safety of BPC-157, GHK-Cu, pinealon, epithalon, GLP-1s, retatrutide, melanotan and growth hormone-promoting peptides. We discuss the gap that exists between animal and human data and meaningful differences in the sources for different peptides. For those interested in peptides, Dr. Bakri provides a grounded look at the science, risks and uncertainties shaping the field today. Read the show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Eight Sleep: https://eightsleep.com/huberman Lingo: https://hellolingo.com/huberman Function: https://functionhealth.com/huberman LMNT: https://drinklmnt.com/huberman Timestamps (00:00:00) Abud Bakri (00:03:33) What are Peptides?, Receptors (00:06:26) BPC-157, Discovery, Animal Proteins (00:11:19) BPC-157, Animal Data, Regeneration (00:12:27) Sponsors: Eight Sleep & Lingo (00:14:51) BPC-157, Regeneration & Healing, Neurological Effects (00:19:27) Adverse Events, Clinical Trials & Legality of BPC-157 (00:29:41) GLPs & Compounding Pharmacy; Peptides & Gray Market (00:35:25) Manufacturing, Compounding Pharmacies, Gray Market, Black Market (00:41:32) Peptides & Tumor Growth?; Angiogenesis (00:45:17) Sponsor: AG1 (00:47:01) Pharmaceutical Patents, Clinical Trials for BPC-157, Potential Outcomes (00:54:19) BPC-157 Healing, Patient Experiences (01:01:22) Physician Counsel, FDA Legality, Malpractice (01:07:25) Pinealon, Epithalon, Discovery; Sleep & Cognitive Performance, Risks (01:18:17) Sponsor: Function (01:19:55) Pineal Age Deterioration, Epithalon, Eye Health (01:29:38) Thymus, Age Shrinkage; Thymosin Alpha-1, Immune Function (01:38:13) TB-500; Pet Health; Thymic Peptide Doses, Thymulin, Zinc (01:49:13) Sponsor: LMNT (01:50:33) GHK-Cu (Copper GHK), Collagen (01:55:32) Illness Recovery, Thymic Score, Tool: Blood Test & Immune Cell Counts (02:04:01) Growth Hormone Secretagogues, Age Decline, Cancer Risk, Insulin (02:15:36) GHK-Cu, Topical Cream, Red Light Therapy (02:20:25) GLPs, Discovery, Physical & Cognitive Long-Term Effects, Fertility (02:33:53) Retatrutide; Drug Patents & Nomenclature (02:39:03) Peptides: Women Reproductive Disorders; TBI, Neurologic Effect; Safe Sources (02:45:34) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices